Trade Summary

6 days ago, Ogden Christopher, serving as CFO at Cytomx Therapeutics, Inc. (CTMX), sold 19,323 shares at $6.42 per share, for a total transaction value of $124,112.00. Following this transaction, Ogden Christopher now holds 296,948 shares of CTMX.

This sale represents a 6.00% decrease in Ogden Christopher's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, 2 days after the trade was made.

Cytomx Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.